<b>Objective </b><br><p>
<i>ABCC8</i> mutations cause neonatal
diabetes that can be transient (TNDM) or less commonly permanent (PNDM); ~90%
individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with <i>ABCC8-</i>PNDM require lower sulfonylurea
doses and have milder neurological features than those with <i>KCNJ11-</i>PNDM. However, these studies were short-term and included
combinations of permanent and transient forms of <i>ABCC8</i>-NDM. We aimed to
assess the long-term glycemic and neurological outcomes in sulfonylurea-treated
<i>ABCC8</i>-PNDM. <b><br>
Research Design and Methods </b><br>
We studied all 24 individuals with <i>ABCC8-</i>PNDM
diagnosed in the UK, Italy, France or USA known to transfer from insulin to sulfonylureas
before May 2010. Data on glycemic
control, sulfonylurea dose, adverse effects including hypoglycemia, and
neurological features were analysed using non-parametric statistical
methods. <b><br>
Results </b><br>
Long-term data were obtained for 21/24 individuals (median follow-up 10.0 (4.1-13.2)
years). 18/21 remained on sulfonylureas
without insulin at most recent follow-up.
Glycemic control improved on sulfonylureas (pre-sulfonylurea vs 1-year post-transfer
HbA1c 7.2% vs 5.7%, p=0.0004) and remained excellent long-term (1-year vs.
10-year HbA1c 5.7% vs. 6.5%, p=0.04), n=16.
Relatively high doses were used (1-year vs 10-year dose 0.37 vs 0.25mg/kg/day
glyburide, p=0.50), without any severe hypoglycemia. Neurological features were reported in 13/21
individuals: these improved following sulfonylurea transfer in 7/13. The commonest features were learning
difficulties (52%), developmental delay (48%), and ADHD (38%).<b><br>
Conclusions </b><br>
Sulfonylurea treatment of <i>ABCC8</i>-PNDM
results in excellent long-term glycemic control. Overt neurological features frequently occur and
may improve with sulfonylureas, supporting early, rapid genetic testing to
guide appropriate treatment and neurodevelopmental assessment. </p>